SC US (TTGP)’s BridgeBio Pharma BBIO Stock Holding History

SC US (TTGP)’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$138M	Hold	1,860,364	–	–	1.49%	7
2025 Q4	$142M	Hold	1,860,364	–	–	1.02%	7
2025 Q3	$96.6M	Hold	1,860,364	–	–	0.6%	9
2025 Q2	$80.3M	Hold	1,860,364	–	–	0.57%	9
2025 Q1	$64.3M	Hold	1,860,364	–	–	0.61%	8
2024 Q4	$51M	Hold	1,860,364	–	–	0.41%	12
2024 Q3	$47.4M	Hold	1,860,364	–	–	0.35%	14
2024 Q2	$47.1M	Hold	1,860,364	–	–	0.38%	13
2024 Q1	$57.5M	Hold	1,860,364	–	–	0.43%	13
2023 Q4	$75.1M	Hold	1,860,364	–	–	0.62%	11
2023 Q3	$49.1M	Hold	1,860,364	–	–	0.45%	13
2023 Q2	$32M	Hold	1,860,364	–	–	0.3%	13
2023 Q1	$30.8M	Hold	1,860,364	–	–	0.36%	15
2022 Q4	$14.2M	Hold	1,860,364	–	–	0.19%	15
2022 Q3	$18.5M	Hold	1,860,364	–	–	0.21%	15
2022 Q2	$16.9M	Hold	1,860,364	–	–	0.2%	14
2022 Q1	$18.9M	Hold	1,860,364	–	–	0.12%	16
2021 Q4	$31M	Hold	1,860,364	–	–	0.15%	13
2021 Q3	$87.2M	Hold	1,860,364	–	–	0.49%	9
2021 Q2	$113M	Sell	1,860,364 -684,374	-27%	-$39.1M	0.72%	9
2021 Q1	$157M	Hold	2,544,738	–	–	0.94%	7
2020 Q4	$181M	Hold	2,544,738	–	–	1.08%	7
2020 Q3	$95.5M	Hold	2,544,738	–	–	0.92%	7
2020 Q2	$83M	Hold	2,544,738	–	–	4.87%	3
2020 Q1	$73.8M	Hold	2,544,738	–	–	5.65%	4
2019 Q4	$89.2M	Hold	2,544,738	–	–	3.83%	6
2019 Q3	$54.6M	Hold	2,544,738	–	–	2.42%	8
2019 Q2	$68.6M	Buy	+2,544,738	New	+$69.4M	4.69%	7

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SC US (TTGP)'s BBIO Position: Q1 2026 in Review

SC US (TTGP) held its BridgeBio Pharma (BBIO) position steady in Q1 2026 at 1,860,364 shares worth $138M. The position accounts for 1.49% of the portfolio, ranked #7.

SC US (TTGP) first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. The position peaked at $181M in Q4 2020. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

SC US (TTGP) held 1,860,364 shares of BridgeBio Pharma worth $138M as of Q1 2026.
SC US (TTGP) left its BridgeBio Pharma share count unchanged in Q1 2026.
BridgeBio Pharma made up 1.49% of SC US (TTGP)'s portfolio in Q1 2026, its #7 holding.
SC US (TTGP) first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
SC US (TTGP)'s BridgeBio Pharma position peaked at $181M in Q4 2020.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on SC US (TTGP)'s 13F filing for Q1 2026, filed 14 May 2026.